Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luca Quagliata

Showing results (51-60 of 63) with videos related to

Pageof 7
Sort By:
Journal of Geriatric Oncology|December 19, 2018
Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in older patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10Dirk L Kienle, Daniel Dietrich, Karin Ribi, et al.
Oncotarget|April 13, 2016
Metabolic reprogramming identifies the most aggressive lesions at early phases of hepatic carcinogenesisMarta Anna Kowalik, Giulia Guzzo, Andrea Morandi, et al.
Hepatology (Baltimore, Md.)|October 12, 2013
Long noncoding RNA HOTTIP/HOXA13 expression is associated with disease progression and predicts outcome in hepatocellular carcinoma patientsLuca Quagliata, Matthias S Matter, Salvatore Piscuoglio, et al.
JCO Oncology Practice|August 9, 2023
Compromised Outcomes in Stage IV Non-Small-Cell Lung Cancer With Actionable Mutations Initially Treated Without Tyrosine Kinase Inhibitors: A Retrospective Analysis of Real-World DataJeffrey A Scott, Jochen Lennerz, Melissa Lynne Johnson, et al.
Hepatology (Baltimore, Md.)|February 5, 2016
Oncogenic driver genes and the inflammatory microenvironment dictate liver tumor phenotypeMatthias S Matter, Jens U Marquardt, Jesper B Andersen, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|April 24, 2021
Non-viral gene delivery of the oncotoxic protein NS1 for treatment of hepatocellular carcinomaDominik Witzigmann, Philip Grossen, Cristina Quintavalle, et al.
Nature|March 22, 2018
The protein histidine phosphatase LHPP is a tumour suppressorSravanth K Hindupur, Marco Colombi, Stephen R Fuhs, et al.
Molecular Oncology|January 27, 2016
Integrated analysis of the prostate cancer small-nucleolar transcriptome reveals SNORA55 as a driver of prostate cancer progressionFrancesco Crea, Luca Quagliata, Agnieszka Michael, et al.
Hepatology (Baltimore, Md.)|July 12, 2016
IκB kinaseα/β control biliary homeostasis and hepatocarcinogenesis in mice by phosphorylating the cell-death mediator receptor-interacting protein kinase 1Christiane Koppe, Patricia Verheugd, Jérémie Gautheron, et al.
Cancer Discovery|April 2, 2014
Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatmentElad Horwitz, Ilan Stein, Mariacarla Andreozzi, et al.
Pageof 7

Showing results (51-60 of 63) with videos related to

Sort By:
Pageof 7
Journal of Geriatric Oncology|December 19, 2018
Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in older patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10Dirk L Kienle, Daniel Dietrich, Karin Ribi, et al.
Oncotarget|April 13, 2016
Metabolic reprogramming identifies the most aggressive lesions at early phases of hepatic carcinogenesisMarta Anna Kowalik, Giulia Guzzo, Andrea Morandi, et al.
Hepatology (Baltimore, Md.)|October 12, 2013
Long noncoding RNA HOTTIP/HOXA13 expression is associated with disease progression and predicts outcome in hepatocellular carcinoma patientsLuca Quagliata, Matthias S Matter, Salvatore Piscuoglio, et al.
JCO Oncology Practice|August 9, 2023
Compromised Outcomes in Stage IV Non-Small-Cell Lung Cancer With Actionable Mutations Initially Treated Without Tyrosine Kinase Inhibitors: A Retrospective Analysis of Real-World DataJeffrey A Scott, Jochen Lennerz, Melissa Lynne Johnson, et al.
Hepatology (Baltimore, Md.)|February 5, 2016
Oncogenic driver genes and the inflammatory microenvironment dictate liver tumor phenotypeMatthias S Matter, Jens U Marquardt, Jesper B Andersen, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|April 24, 2021
Non-viral gene delivery of the oncotoxic protein NS1 for treatment of hepatocellular carcinomaDominik Witzigmann, Philip Grossen, Cristina Quintavalle, et al.
Nature|March 22, 2018
The protein histidine phosphatase LHPP is a tumour suppressorSravanth K Hindupur, Marco Colombi, Stephen R Fuhs, et al.
Molecular Oncology|January 27, 2016
Integrated analysis of the prostate cancer small-nucleolar transcriptome reveals SNORA55 as a driver of prostate cancer progressionFrancesco Crea, Luca Quagliata, Agnieszka Michael, et al.
Hepatology (Baltimore, Md.)|July 12, 2016
IκB kinaseα/β control biliary homeostasis and hepatocarcinogenesis in mice by phosphorylating the cell-death mediator receptor-interacting protein kinase 1Christiane Koppe, Patricia Verheugd, Jérémie Gautheron, et al.
Cancer Discovery|April 2, 2014
Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatmentElad Horwitz, Ilan Stein, Mariacarla Andreozzi, et al.
Pageof 7